Aclaris Therapeutics, Inc. · NASDAQ:ACRS
Aclaris Therapeutics — Investor Presentation (April 2023)
28 slides from Aclaris Therapeutics's investor presentation, Apr 14, 2023
Slide 1: Corporate Overview April 2023
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Corporate Overview April 2023 EMPOWERING PATIENTS THROUGH KINOME INNOVATION
Slide 2: Cautionary Note Regarding Forward-Looking Statements
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not describe historical facts may constitute forward-looki
Slide 3: Biotechnology Company Focused on the Kinome
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Biotechnology Company Focused on the Kinome People + Platform + Pipeline 3 Note: KINect® is the registered trademark of Aclaris Therapeutics, Inc. Leadership Scientifi
Slide 4: The Kinase Opportunity: Unlocking the Potential of the Kinome
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) The Kinase Opportunity Unlocking the Potential of the Kinome 4 Note: All trademarks are the property of their respective owners. 1. GoodRx. Accessed January 4, 2023. h
Slide 5: Precision Immunology with the KINect Platform
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Precision Immunology with the KINect Platform Demonstrated Success in Reversible and Covalent MOA 5 MK2 Inhibitors Unique kinase complex inhibitor • Zunsemetinib (ATI-
Slide 6: Drug Development Pipeline
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Drug Development Pipeline 6 Drug Candidate / Program Target Route of Administration Indication Development Phase Topline Data Expected Immuno-Inflammatory Diseases Zun
Slide 7: Zunsemetinib (ATI-450): MK2 Inhibitor
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved 7 Zunsemetinib (ATI-450): MK2 Inhibitor (Investigational Drug Candidate)
Slide 8: Evolution in Understanding of a Well-Known Path
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Evolution in Understanding of a Well-Known Path 8 Note: Wang C, et al. J Exp Med. 2018;215(5):1315-1325; Cheung P, et al. EMBO J. 2003;22(21):5793-5805; Muniyappa H, e
Slide 9: Novel Mechanism: Locking MK2 in an Inactive State
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Novel Mechanism: Locking MK2 in an Inactive State 9 Note: Wang C, et al. J Exp Med. 2018;215(5):1315-1325. • In the nucleus, inactive MK2 and p38α dock in a high affin
Slide 10: Zunsemetinib: Investigational Small Molecule, Oral MK2 Inhibitor
© Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved Zunsemetinib: Investigational Small Molecule, Oral MK2 Inhibitor Designed to Block the Targets of Broadly-Used Biologics 10 1. Data on file; 2. Fortune Business Insights. A
Slide 11: Zunsemetinib Demonstrated Strong Inhibition Across Key Cytokines
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Zunsemetinib Demonstrated Strong Inhibition Across Key Cytokines 11 Note: Data on file Zunsemetinib dosed orally BID for 7 days in healthy subjects at doses of 10, 30
Slide 12: Zunsemetinib Phase 2a Trial in Rheumatoid Arthritis
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Zunsemetinib Phase 2a Trial in Rheumatoid Arthritis Summary of Clinical Data 12 Summary of Efficacy Endpoints Potent and Durable Clinical Efficacy with 50mg Main Objec
Slide 13: Clinical Development: Zunsemetinib
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Phase 2 Clinical Development: Zunsemetinib 13 Hidradenitis Suppurativa 12-week phase 2a randomized trial Psoriatic Arthritis 12-week phase 2a randomized trial Trial si
Slide 14: Hidradenitis Suppurativa Phase 2a Topline Data
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) • Preliminary topline data announced in March 2023 ✓Zunsemetinib in HS did not meet any primary or secondary efficacy endpoints ✓PD profile of zunsemetinib in trial de
Slide 15: ATI-1777 (Topical Soft JAK Inhibitor)
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved 15 ATI-1777 (Topical “Soft” JAK Inhibitor) (Investigational Drug Candidate)
Slide 16: Aiming to Develop an Effective and Safe Therapy for Atopic Dermatitis
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Aiming to Develop an Effective and Safe Therapy for Atopic Dermatitis 16 1. Medscape. Accessed January 7, 2023. https://emedicine.medscape.com/article/1049085-overview
Slide 17: Positive Data Demonstrated in ATI-1777 Phase 2a Study
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Positive Data Demonstrated in ATI-1777 Phase 2 Study in Atopic Dermatitis 17 0 20 40 60 80 100 mEASI50 mEASI75 mEASI90 ATI-1777 Vehicle Primary Efficacy Endpoint: % Ch
Slide 18: Low Plasma Levels of ATI-1777 Following Topical Application
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Low Plasma Levels of ATI-1777 Following Topical Application 18 Note: Data on file • All concentrations < ½ IC50 (IC50 = 36 ng/mL for JAK1/3) • >86% of samples tested f
Slide 19: ATI-1777 Status
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ATI-1777 Status 19 Positive Proof of Concept First in Human Study • Moderate to Severe Atopic Dermatitis ✓ Traditionally the domain of systemic therapy • Rapid and con
Slide 20: ATI-2138 (ITK/JAK3 Inhibitor)
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved 20 ATI-2138 (ITK/JAK3 Inhibitor) (Investigational Drug Candidate)
Slide 21: ATI-2138: Covalent ITK/JAK3 Inhibitor
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ATI-2138: Covalent ITK/JAK3 Inhibitor with Potential for Ulcerative Colitis and other T Cell-Mediated Diseases 21 1. Data on file; 2. Graham RM. Cleve Clin J Med. 1994
Slide 22: ITK and JAK3 Pathways Dose-Dependently Inhibited by ATI-2138
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Simultaneous Stimulation of the ITK and JAK3 Pathways was Dose-Dependently Inhibited by ATI-2138 22 Assesses modulation of both ITK and JAK3 via αCD3/IL-15- induced IF
Slide 23: Wide Array of Disease Targets for ATI-2138
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) cGvHD Genital Psoriasis Acute Inflammatory Psoriasis Acute Severe Ulcerative Colitis Asthma SLE RA Crohn’s Disease Transplant Ulcerative Colitis Ulcerative Colitis Sel
Slide 24: Corporate Highlights
© Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved 24 Corporate Highlights
Slide 25: Empowering Patients Through Kinome Innovation
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Empowering Patients Through Kinome Innovation 25 Proven track record of R&D, business development and scientific leadership in immuno-inflammatory diseases Proprietary
Slide 26: Experienced Leadership Team
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Experienced Leadership Team 26 Douglas Manion Chief Executive Officer Joseph Monahan Chief Scientific Officer James Loerop Chief Business Officer Gail Cawkwell Chief M
Slide 27: Drug Development Pipeline
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Drug Development Pipeline 27 Drug Candidate / Program Target Route of Administration Indication Partner Development Phase Immuno-Inflammatory Diseases Zunsemetinib (AT
Slide 28: 2023 Expected Data Readouts
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) 2023 Expected Data Readouts 28 Mid 2023 H2 2023 Topline Announced March 2023 H2 2023 ATI-1777 AD Phase 2b ATI-2138 Phase 1 Multiple Ascending Dose ATI-450 HS Phase 2a
Aclaris Therapeutics — Investor Presentation (April 2023) on 6ix